86189-69-7

Basic information

• Product Name: Felodipine
• Synonyms: 4-(2,3-DICHLOROPHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5-PYRIDINECARBOXYLIC ACID METHYL ESTER;4-(2,3-DICHLOROPHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5-PYRIDINEDICARBOXYLIC ACID METHYL ESTER;FLODIL;FELODAY;ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate;Felodipine;Agon sr;Brn 4331472
• CAS NO: 86189-69-7
• Molecular Formula: C18H19Cl2NO4
• Molecular Weight: 384.25
• Mol File: 86189-69-7.mol
• Article Data: 25

Chemical Properties

• Melting Point: 142-145℃
• Boiling Point: 471.5 °C at 760 mmHg
• Flash Point: 239 °C
• Appearance: light yellow/solid
• Density: 1.277 g/cm³
• Vapor Pressure: 4.62E-09mmHg at 25°C
• Refractive Index: 1.549
• Solubility: DMSO: 28 mg/mL
• Water Solubility: insoluble
• CAS DataBase Reference: Felodipine(CAS DataBase Reference)
• NIST Chemistry Reference: Felodipine(86189-69-7)
• EPA Substance Registry System: Felodipine(86189-69-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Safety Statements: S36:
• WGK Germany: 3
• RTECS: US7968700
• Hazardous Substances Data: 86189-69-7(Hazardous Substances Data)

Usage

Clinical Use

Calcium-channel blocker:HypertensionAngina

Drug interactions

Potentially hazardous interactions with other drugs Aminophylline and theophylline: possibly increased aminophylline and theophylline concentration. Anaesthetics: enhanced hypotensive effect. Antibacterials metabolism possibly inhibited by clarithromycin, erythromycin and telithromycin. Antidepressants: enhanced hypotensive effect with MAOIs. Antiepileptics: effect reduced by carbamazepine, barbiturates, phenytoin and primidone. Antifungals: metabolism inhibited by itraconazole and ketoconazole; negative inotropic effect possibly increased with itraconazole. Antihypertensives: enhanced hypotensive effect, increased risk of first dose hypotensive effect of postsynaptic alpha-blockers. Antivirals: concentration possibly increased by ritonavir; use with caution with telaprevir. Grapefruit juice: concentration increased - avoid concomitant use. Tacrolimus: possibly increased tacrolimus concentration

Metabolism

Felodipine is metabolised in the liver and all identified metabolites are devoid of vasodilating properties. Approximately 70% of a given dose is excreted as metabolites in the urine and about 10% with the faeces. Less than 0.5% of the dose is excreted unchanged in the urin

InChI:InChI=1/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3

Upstream product

• 88-12-0 1-ethenyl-2-pyrrolidinone 
• 64-17-5 ethanol 
• 72509-76-3 ethyl methyl 1,4-dihydro-2,6-dimethyl-4(2,3-dichlorophenyl)-3,5-pyridinedicarboxylate 
• 127634-11-1 (R)-4-(2,3-Dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-[(R)-1-hydroxymethyl-2-(toluene-4-sulfonyl)-ethyl] ester 
• 1215080-63-9 (2R)-1-(phenylthio)-3-(tetrahydro-2H-pyran-2-yloxy)propan-2-yl 2-(2,3-dichlorobenzylidene)-3-oxobutanoate 
• 1215080-64-0 (4S)-3-ethyl 5-(1-(phenylthio)-3-(tetrahydro-2H-pyran-2-yloxy)propan-2-yl) 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
• 1215080-66-2 (R)-3-ethyl 5-((R)-1-hydroxy-3-(phenylthio)propan-2-yl) 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate 
• 124-41-4 sodium methylate 
• 1352187-22-4 C₂₆H₂₇Cl₂NO₇S 
• 74-88-4 methyl iodide 
• 127634-13-3 (S)-4-(2,3-Dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid monoethyl ester 
• 127634-12-2 (S)-4-(2,3-Dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-[(R)-1-hydroxymethyl-2-(toluene-4-sulfonyl)-ethyl] ester 
• 127634-14-4 (R)-4-(2,3-Dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid monoethyl ester 
• 626-34-6 ethyl 3-aminobut-2-enoate 

Relevant articles and documents

METHODS FOR TREATING CHRONIC FATIGUE SYNDROME AND MYALGIC ENCEPHALOMYELITIS

In one aspect the invention relates to a method of treatment selected from the group consisting of: (a) treating a symptom such as pain in a subject identified or diagnosed as having Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS); (b) treating a symptom such as pain in a subject having dysfunctional TRPM3 ion channel activity; (c) restoring NK cell function in a subject having dysfunctional TRPM3 ion channel activity; and (d) restoring calcium homeostasis in a subject having dysfunctional TRPM3 ion channel activity. The method comprises the step of administering to the subject a therapeutically effective amount of at least one therapeutic compound selected from the group consisting of: (i) an opioid receptor antagonist; (ii) an opioid antagonist; and (iii) a therapeutic compound that restores TRPM3 ion channel activity. In some embodiments the therapeutic compound is naltrexone hydrochloride.

An efficient and recyclable 3D printed α-Al2O3 catalyst for the multicomponent assembly of bioactive heterocycles

A catalytic methodology is reported that enables the efficient, operationally simple and environmentally friendly synthesis of diverse 1,4-dihydropyridines and 3,4-dihydropyrimidin-2(1H)-ones, including some relevant drugs and pharmacologically active derivatives. This strategy is based on the use of a 3D printed Al2O3 woodpile material that was sintered to generate a rigid structure with controlled porosity and noteworthy catalytic performance. The 3D printed Al2O3 catalyst exhibits remarkable efficacy as a Lewis acid in Biginelli and Hantzsch reactions and it can be recovered and reused ten times without any decrease in the activity. Remarkable E factors, excellent recyclability and scalability, broad substrate scope, short reaction times, excellent yields, solvent-free conditions and easy isolation procedures are key features of this methodology.

Metal-free-mediated oxidation aromatization of 1,4-dihydropyridines to pyridines using visible light and air

A metal-free and environmentally friendly aerobic aromatization photosensitized by organic dye eosin Y bis(tetrabutyl ammonium salt) (TBA-eosinY) has been developed. With the aid of K2CO3, the aerobic catalytic system converts 1,4-dihydropyridines to their corresponding pyridine derivatives efficiently under visible light irradiation (λ=450 nm) at room temperature.